Zofran MDL Judge Denies Dismissal For Lack Of ‘Clear Evidence’ Of FDA Action
BOSTON — GlaxoSmithKline LLC’s attempt to dismiss the Zofran multidistrict litigation before discovery began is premature, a Massachusetts federal judge ruled Jan. 22 (In Re: Zofran [Ondansetron] Products Liability Litigation, MDL...To view the full article, register now.
Already a subscriber? Click here to view full article